SUTRO BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.42 USD | 0.00% |
|
-5.79% | -20.28% |
| Sales 2024 * | 71.73M 5.74B | Sales 2025 * | 60.34M 4.83B | Capitalization | 280M 22.39B |
|---|---|---|---|---|---|
| Net income 2024 * | -217M -17.37B | Net income 2025 * | -260M -20.81B | EV / Sales 2024 * | 1.61 x |
| Net cash position 2024 * | 164M 13.14B | Net cash position 2025 * | 368M 29.46B | EV / Sales 2025 * | -1.46 x |
| P/E ratio 2024 * |
-1.04
x | P/E ratio 2025 * |
-1.05
x | Employees | 302 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.03% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sutro Biopharma, Inc.
More recommendations
More press releases
More news
| 1 week | -5.79% | ||
| Current month | -39.47% | ||
| 1 month | -18.18% | ||
| 3 months | -27.23% | ||
| 6 months | +25.74% | ||
| Current year | -20.28% |
1 week
3.30
3.94
1 month
3.306.13
Current year
3.206.13
1 year
2.016.13
3 years
2.0123.70
5 years
2.0128.30
10 years
2.0128.30
| Managers | Title | Age | Since |
|---|---|---|---|
William Newell
CEO | Chief Executive Officer | 66 | 13/01/09 |
Jane Chung
PSD | President | 53 | 08/08/21 |
Edward Albini
DFI | Director of Finance/CFO | 66 | 30/01/13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Connie Matsui
CHM | Chairman | 70 | 23/06/19 |
James Panek
BRD | Director/Board Member | 71 | 06/01/20 |
Daniel Petree
BRD | Director/Board Member | 68 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 9 M€ | +6.26% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 3.42 | 0.00% | 474,120 |
| 25/04/24 | 3.42 | -1.44% | 538,890 |
| 24/04/24 | 3.47 | -6.72% | 731,249 |
| 23/04/24 | 3.72 | -1.33% | 722,440 |
| 22/04/24 | 3.77 | +3.86% | 515,209 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Companyâs advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.42
USD
Average target price
12.89
USD
Spread / Average Target
+276.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.28% | 263M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- STRO Stock
